Lilly Falls as Weight-Loss Pill Data Overshadows Sales Beat

单集文稿 ...

• 00:02

  Hi, I'm Lisa Mateo, introducing you to the new Stock Movers Report from Bloomberg.

• 00:08

  These are short audio reports, five minutes or less,

• 00:11

  delivered right to your podcast feed throughout the day.

• 00:14

  Stock Movers fills you in on the day's winners and losers on Wall Street and tells you about the news and data that's driving those gains and losses.

• 00:22

  If you want to stay plugged into the stock market but don't want to spend all day watching tickers scroll across your screen,

• 00:29

  then Stock Movers is a place for you to get informed.

• 00:33

  Listen a couple times throughout the day to find out what's moving equities.

• 00:43

  Get the latest stock news and data backed by reporting from Bloomberg's 3,000 journalists and analysts across the globe.

• 00:52

  Subscribe to Stock Movers wherever you get your podcasts.

• 01:17

  Listen on demand wherever you get your podcasts.

• 01:21

  Or watch us live on YouTube.

• 01:23

  Eli Lilly.

• 01:25

  It had a sales beat, but shares are taking a hit.

• 01:27

  Yeah, Lilly shares are down about 14%.

• 01:29

  There is something overshadowing that.

• 01:31

  For that, we're going to bring in Damien Gardez, Bloomberg News health reporter.

• 01:35

  Damien, thanks for joining us here in the studio.

• 01:37

  So it looks like this experiment, this drug, experimental weight loss pill,

• 01:42

  and that's the thing here, it didn't do as well in the study as Wall Street had expected.

• 01:47

  Exactly.

• 全部文稿